Trial · NCT01698710
Endoscopic Abraxane Injection Into Pancreatic Cysts
NCT01698710, Not applicable, Terminated, Massachusetts General Hospital; results first posted 2017-06-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Endoscopic Abraxane Injection Into Pancreatic Cysts. Trials, record NCT01698710. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01698710
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Endoscopic Abraxane Injection Into Pancreatic Cysts
- NCT number
- NCT01698710
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 5 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Pancreatic Cysts
- Interventions
- Albumin bound paclitaxel
- First posted
- 2012-10-03
- Last updated
- 2017-06-21
- Results first posted
- 2017-06-21
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency of Pancreatitis | 3-10 months (median 6 months) after injection therapy | Safety of injection of albumin-bound paclitaxel will be measured by the frequency of pancreatitis. |
| Secondary | Feasibility of Endoscopic Ultrasonography (EUS) Guided Injection of Albumin-bound Paclitaxel Into Pancreatic Cysts | immediately after procedure | The feasibility of the procedure will be measured by the ease of injection of albumin-bound paclitaxel into the cyst cavity across the gastro-duodenal wall. On a subjective scale, the endoscopist will note the ease of the procedure on a scale of 0-5, with 5 being very easy and 0 is not possible. Any score less than 2 will be considered unacceptable and failure of the study. |
| Secondary | Size of Cystic Lesion | 3-10 months (median 6 months) after injection therapy | Determine the size of the cystic lesion using CT scanning. Number of participants with reduction in size, persistent size, or increase in size of cyst are reported. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Frequency of Pancreatitis | 3-10 months (median 6 months) after injection therapy | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Feasibility of Endoscopic Ultrasonography (EUS) Guided Injection of Albumin-bound Paclitaxel Into Pancreatic Cysts | immediately after procedure | units on a scale | MEDIAN | |
| SECONDARY | Size of Cystic Lesion | 3-10 months (median 6 months) after injection therapy | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Frequency of Pancreatitis | Albumin Bound Paclitaxel | 0 | Participants | ||
| Feasibility of Endoscopic Ultrasonography (EUS) Guided Injection of Albumin-bound Paclitaxel Into Pancreatic Cysts | Albumin Bound Paclitaxel | 4 | Full Range 3 to 5 | units on a scale | |
| Size of Cystic Lesion | Albumin Bound Paclitaxel | Reduction | 3 | Participants | |
| Size of Cystic Lesion | Albumin Bound Paclitaxel | Persistent | 1 | Participants | |
| Size of Cystic Lesion | Albumin Bound Paclitaxel | Increase | 1 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Albumin Bound Paclitaxel | 5 | |
| Overall Study | COMPLETED | Albumin Bound Paclitaxel | 5 | |
| Overall Study | NOT COMPLETED | Albumin Bound Paclitaxel | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Albumin Bound Paclitaxel | ||
| Total, other adverse events | Albumin Bound Paclitaxel | 0 | 5 |
| Total, serious adverse events | Albumin Bound Paclitaxel | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01698710
GET https://conductscience.org/api/trials/v1/NCT01698710/registered